Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Provincial Government of Central Java, Indonesia | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of hypoxia-mesenchymal stem cells. The improvement in clinical, laboratory, and radiological manifestations will be evaluated in treated patients compared with the control group.
The devastating effect of severe acute respiratory syndrome coronavirus-2 (SARS COV-2) infection is caused by a robust cytokine storm that leads to lung tissue damage. Several studies reported a correlation between disease severity and the release of excessive proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), IL-6, IL-1, IFN-Υ, IFN-Υ-induced protein 10 (IP10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1a (MIP-1a), and granulocyte-colony stimulating factor (G-CSF). This finding was confirmed by the high level of plasma cytokines found in most severe COVID-19 patients associated with extensive lung damage. Therefore, finding an effective therapeutic option to control the devastating cytokine storm of COVID-19 and regenerate the damaged lung is crucial.
Previous studies reported that the hypoxic condition of MSCs could enhance the release of their active soluble molecules known as Secretome-MSCs (S-MSCs), such as IL-10 and TGF-β that useful in alleviating inflammation. Moreover, they could also increase the expression of growth factors such as VEGF and PDGF that accelerate lung injury improvement. These active molecules could potentially serve as a biological therapeutic agent for treating the severe SARS-CoV-2 infection. According to recent studies, we successfully isolated the S-MSCs from their culture medium using tangential flow filtration (TFF) strategy with several molecular weight cut-off category. This study investigated the clinical outcomes of severe COVID-19 patients with several comorbidities treated with S-MSCs in Indonesia.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Secretome-MSCs (n=24) | Experimental | This group will be given Covid-19 standard therapy with intramuscular Hypoxic S-MSC secretome |
|
| Control (n=24) | Other | This group will receive standard Covid-19 therapy with the best supportive care |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Injection of Secretome-MSCs | Biological | Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) : Day 1: 1 cc every 12 hours Day 2: 1 cc every 12 hours Day 3: 1 cc every 12 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Change in patients clinical manifestation | mild, moderate, or severe | 1 months |
| Need for a ventilator | There are respiratory variables that made severe Covid-19 patients previously stable but worsened, requiring a ventilator Divided into two categories:
| 1 months |
| Duration of using a ventilator | Duration of use of a ventilator from the day of intubation to the day of extubation | 1 months |
| Length of stay | The length of stay from the first treatment to the patient's final outcome, recovery, or death | 1 months |
| Routine blood profile | Obtained from patients before and after treatment | 2 weeks |
| CRP | Obtained from patients before and after treatment | 2 weeks |
| D-dimer | Obtained from patients before and after treatment | 2 weeks |
| Blood Gas Analisis (BGA) | Obtained from patients before and after treatment | 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Survival | Death | 2 months |
Not provided
Inclusion Criteria:
Patients whose clinical and laboratory test results have a positive diagnosis of Covid-19.
Patients who are willing to participate as subjects in the study by signing the informed content.
Criteria for Berlin to enter ARDS (moderate and severe) with or without a ventilator:
One or more comorbid history
SOFA score
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Agung Putra, Assoc.Prof | Contact | +628164251646 | dr.agungptr@gmail.com | |
| Bhirau Wilaksono, MD | Contact | +6285277777824 | bhirau@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Agung Putra, Assoc.Prof | Stem Cell and Cancer Research Indonesia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| RSUD Bantul | Recruiting | Bantul | Central Java | Indonesia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31986264 | Background | Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. | |
| 32105632 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Standard treatment of Covid-19 | Drug | Patients will be given Standard treatment of Covid-19 which accordance with National protocol |
|
| Photo thorax | Obtained from patients before and after treatment | 2 weeks |
| RS PKU Muhammadiyah Gamping | Recruiting | Yogyakarta | Central Java | 55122 | Indonesia |
|
| RS Primaya Bekasi Timur | Recruiting | Bekasi | Jakarta Special Capital Region | Indonesia |
|
| Bhayangkara Hospital | Recruiting | Makassar | South Celebes | Indonesia |
|
| Gatot Soebroto Army Hospital | Recruiting | Jakarta | 10410 | Indonesia |
|
| Dr. Esnawan Antariksa Air Force Hospital | Recruiting | Jakarta | 13610 | Indonesia |
|
| Background |
| Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. |
| 24781370 | Background | Chen L, Xu Y, Zhao J, Zhang Z, Yang R, Xie J, Liu X, Qi S. Conditioned medium from hypoxic bone marrow-derived mesenchymal stem cells enhances wound healing in mice. PLoS One. 2014 Apr 29;9(4):e96161. doi: 10.1371/journal.pone.0096161. eCollection 2014. |
| 30341012 | Background | Haraszti RA, Miller R, Stoppato M, Sere YY, Coles A, Didiot MC, Wollacott R, Sapp E, Dubuke ML, Li X, Shaffer SA, DiFiglia M, Wang Y, Aronin N, Khvorova A. Exosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity. Mol Ther. 2018 Dec 5;26(12):2838-2847. doi: 10.1016/j.ymthe.2018.09.015. Epub 2018 Sep 22. |
| 33274176 | Result | Harrell CR, Jovicic BP, Djonov V, Volarevic V. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome. Anal Cell Pathol (Amst). 2020 Nov 20;2020:1939768. doi: 10.1155/2020/1939768. eCollection 2020. |
| 32747157 | Result | Johnson BS, Laloraya M. A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization. Cytokine Growth Factor Rev. 2020 Aug;54:32-42. doi: 10.1016/j.cytogfr.2020.06.014. Epub 2020 Jul 1. |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D000080424 | Cytokine Release Syndrome |
| D000860 | Hypoxia |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |
| D012818 | Signs and Symptoms, Respiratory |
| D012816 | Signs and Symptoms |
Not provided
Not provided